If semaglutide reduces blood sugar to normal levels, the kidneys no longer need to excrete large amounts of glucose
If you cannot keep fluids down, call your clinician because IV fluids may be needed in some cases
A thin, even layer is usually enough to cover the intended area
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
For US-based researchers, it is available through the research peptide market but not through pharmacies or prescription
11: 141720 Woolf CJ, Shortland P, Reynolds H, et al